On March 3, 2020 Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing treatments for cancer and other serious diseases, reported it will be presenting at the third annual LD Micro Virtual Conference on Wednesday, March 4 at 1:40 p.m. EST (Press release, Genprex, MAR 3, 2020, View Source [SID1234555117]). Genprex’s Chairman and Chief Executive Officer, Rodney Varner, will lead the company’s presentation and will be answering questions from investors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live presentation, please use the following link: http://bit.ly/2PFjomt.

"We are delighted to be hosting our third virtual event in order to showcase some of the truly unique names in micro-cap," stated Chris Lahiji, President of LD Micro. "There are many people and companies who are unable to attend our live events due to any number of reasons, so we are happy to offer an additional way for companies to present to investors without taking a lot of time out of their day-to-day operations. While virtual events will never replace the experience of sitting in the same room as other humans, it is a great format for updating the investor community and getting increased exposure."

The conference will be held via webcast and will feature more than 40 companies in the small/micro-cap space.